| LDR | | 00000nmm u2200205 4500 |
| 001 | | 000000330652 |
| 005 | | 20241104115340 |
| 008 | | 181129s2017 ||| | | | eng d |
| 020 | |
▼a 9780438097766 |
| 035 | |
▼a (MiAaPQ)AAI10901832 |
| 035 | |
▼a (MiAaPQ)OhioLINK:osu1510592650256558 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
| 049 | 1 |
▼f DP |
| 082 | 0 |
▼a 574 |
| 100 | 1 |
▼a Ruppert Stark, Amy S. |
| 245 | 10 |
▼a Early Clinical Trial Design Recommendations in Oncology Based on Overall Success across Phases I, II, and III. |
| 260 | |
▼a [S.l.] :
▼b The Ohio State University.,
▼c 2017 |
| 260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2017 |
| 300 | |
▼a 204 p. |
| 500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B. |
| 500 | |
▼a Adviser: Abigail Shoben. |
| 502 | 1 |
▼a Thesis (Ph.D.)--The Ohio State University, 2017. |
| 520 | |
▼a Conventionally, drug development has spanned three distinct phases, and the success rate for experimental drugs across phases has been less than 15% (Hay, Thomas, Craighead, Economides, and Rosenthal, 2014). Despite increased options for nonstan |
| 520 | |
▼a Phase I, II, and III trials were simulated for clinical scenarios defined by eight toxicity profiles and two nondecreasing efficacy profiles. Early results showed that correctly selecting the maximum tolerated dose (MTD) greatly impacted overall |
| 520 | |
▼a Based on our results, we make the following recommendations for design selection when data informing the shape of the dose-toxicity curve exist. If a large jump in toxicity between dose levels is expected, we recommend the standard 3+3 design, w |
| 590 | |
▼a School code: 0168. |
| 650 | 4 |
▼a Biostatistics. |
| 690 | |
▼a 0308 |
| 710 | 20 |
▼a The Ohio State University.
▼b Biostatistics. |
| 773 | 0 |
▼t Dissertation Abstracts International
▼g 79-12B(E). |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0168 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2017 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T15000279
▼n KERIS |
| 980 | |
▼a 201812
▼f 2019 |
| 990 | |
▼a 관리자
▼b 관리자 |